Evidence map›Paper›PMID 29295717›Full record

ArticleBMC cancer2018

Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations.

René Böttcher, Charlotte F Kweldam, Julie Livingstone, Emilie Lalonde, Takafumi N Yamaguchi, Vincent Huang, Fouad Yousif, Michael Fraser, Robert G Bristow, Theodorus van der Kwast and 3 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed
10.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 122 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Observational
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

René BöttcherDepartment of Urology, Erasmus MC, Rotterdam, the Netherlands.
Charlotte F KweldamDepartment of Pathology, Erasmus University Medical Center, Josephine Nefkens Institute building, Be-222, P.O. Box 2040, Rotterdam, 3000 CA, The Netherlands.
Julie LivingstoneInformatics & Biocomputing Program, Ontario Institute for Cancer Research, Toronto, ON, Canada.
Emilie LalondeInformatics & Biocomputing Program, Ontario Institute for Cancer Research, Toronto, ON, Canada.
Takafumi N YamaguchiInformatics & Biocomputing Program, Ontario Institute for Cancer Research, Toronto, ON, Canada.
Vincent HuangInformatics & Biocomputing Program, Ontario Institute for Cancer Research, Toronto, ON, Canada.
Fouad YousifInformatics & Biocomputing Program, Ontario Institute for Cancer Research, Toronto, ON, Canada.
Michael FraserOntario Cancer Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Robert G BristowDepartment of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
Theodorus van der KwastDepartment of Pathology and Laboratory Medicine, Toronto General Hospital, University Health Network, Toronto, ON, Canada.
Paul C BoutrosInformatics & Biocomputing Program, Ontario Institute for Cancer Research, Toronto, ON, Canada.
Guido JensterDepartment of Urology, Erasmus MC, Rotterdam, the Netherlands.
Geert J L H van LeendersDepartment of Pathology, Erasmus University Medical Center, Josephine Nefkens Institute building, Be-222, P.O. Box 2040, Rotterdam, 3000 CA, The Netherlands. g.vanleenders@erasmusmc.nl.
Ontario Institute for Cancer Research · CAErasmus MC · NLUniversity of Toronto · CAErasmus University Rotterdam · NLToronto General Hospital · CAUniversity Health Network · CA

Funding

Center for Translational Molecular Medicine 03O-402CIHR New Investigator AwardMovember Foundation #RS2014-01Terry Fox Research Institute New Investigator Award
6 · The paper itself

Abstract

backgroundInvasive cribriform and intraductal carcinoma (CR/IDC) is associated with adverse outcome of prostate cancer patients. The aim of this study was to determine the molecular aberrations associated with CR/IDC in primary prostate cancer, focusing on genomic instability and somatic copy number alterations (CNA).

methodsWhole-slide images of The Cancer Genome Atlas Project (TCGA, N = 260) and the Canadian Prostate Cancer Genome Network (CPC-GENE, N = 199) radical prostatectomy datasets were reviewed for Gleason score (GS) and presence of CR/IDC. Genomic instability was assessed by calculating the percentage of genome altered (PGA). Somatic copy number alterations (CNA) were determined using Fisher-Boschloo tests and logistic regression. Primary analysis were performed on TCGA (N = 260) as discovery and CPC-GENE (N = 199) as validation set.

resultsCR/IDC growth was present in 80/260 (31%) TCGA and 76/199 (38%) CPC-GENE cases. Patients with CR/IDC and ≥ GS 7 had significantly higher PGA than men without this pattern in both TCGA (2.2 fold; p = 0.0003) and CPC-GENE (1.7 fold; p = 0.004) cohorts. CR/IDC growth was associated with deletions of 8p, 16q, 10q23, 13q22, 17p13, 21q22, and amplification of 8q24. CNAs comprised a total of 1299 gene deletions and 369 amplifications in the TCGA dataset, of which 474 and 328 events were independently validated, respectively. Several of the affected genes were known to be associated with aggressive prostate cancer such as loss of PTEN, CDH1, BCAR1 and gain of MYC. Point mutations in TP53, SPOP and FOXA1were also associated with CR/IDC, but occurred less frequently than CNAs.

conclusionsCR/IDC growth is associated with increased genomic instability clustering to genetic regions involved in aggressive prostate cancer. Therefore, CR/IDC is a pathologic substrate for progressive molecular tumour derangement.

Indexed as

DNA Copy Number VariationsGenomic InstabilityAdenocarcinomaAgedBiomarkers, TumorCarcinoma, Intraductal, NoninfiltratingFollow-Up StudiesGenomicsHumansMaleMiddle AgedPrognosisProstatic NeoplasmsBiomarkers, TumorAggressive diseaseCopy number alterationCribriformGenomic instabilityIntraductal carcinomaProstate cancer

Identifiers

PMID29295717
PMCPMC5751811
OpenAlexW2781627972

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.